摘要
目的:探讨普适泰治疗慢性ⅢA型前列腺炎患者的疗效及对前列腺液干扰素-γ(IFN-γ)、转化生长因子-β1(TGF-β1)的影响。方法:选择2018年1月至2019年6月我院接诊的120例慢性ⅢA型前列腺炎患者,通过随机数表法分为观察组和对照组,每组60例。在常规处理基础上,对照组给予左氧氟沙星、坦索罗辛缓释胶囊治疗,观察组在对照组基础上,联合普适泰片治疗,均连续治疗连续用药12周。比较两组临床疗效、美国国立卫生研究院慢性前列腺炎症状指数(NIH-CPSI)、前列腺液白细胞计数(WBC)、卵磷脂小体(HP)、IFN-γ、TGF-β1的变化及不良反应。结果:治疗后,观察组临床疗效总有效率为93.33%,明显高于对照组的78.33%,差异有统计学意义(P<0.05);观察组NIH-CPSI评分中疼痛和不适、排尿症状、症状严重程度及总分均明显低于对照组[(5.05±0.69)vs(6.33±0.74)分,(1.56±0.43)vs(2.70±0.55)分,(6.31±1.50)vs(7.92±1.64)分,(12.92±2.44)vs(16.95±2.87)分],差异有统计学意义(P<0.05);观察组前列腺液WBC、IFN-γ、TGF-β1明显低于对照组[(8.52±1.70)vs(10.04±1.58)个/HP,(8.06±1.32)vs(9.72±1.61)ng/L,(27.34±3.06)vs(42.57±3.89)ng/L],HP明显比对照组高[(81.06±5.75)vs(70.22±6.31)%],差异有统计学意义(P<0.05);两组治疗期间恶心呕吐、乏力、心悸的总发生率比较差异无统计学意义(P>0.05)。结论:在常规治疗基础上,联合普适泰治疗治疗慢性ⅢA型前列腺炎患者疗效显著,可有效促进症状恢复,降低前列腺液IFN-γ、TGF-β1的表达,且不增加不良反应,值得应用推广。
Objective: To study the effect of prostat in the treatment of chronic ⅢA prostatitis and its effects on prostatic fluid interferon-γ(IFN-γ) and transforming growth factor-β1(TGF-β1) levels. Methods: 120 patients of chronic ⅢA prostatitis who received therapy from January 2018 to June 2019 in our hospital were selected, according to the random number table, they were divided into the observation group and the control group, each group had 60 cases. On the basis of routine treatment, the control group was treated with levofloxacin and tamsulosin sustained-release capsule, and the observation group was combined with prostat tablet on the basis of the control group, they were treated continuously for 12 weeks. The clinical efficacy, the National Institutes of Health Chronic Prostatitis Symptom Index(NIH-CPSI), prostatic fluid white blood cell count(WBC), lecithin corpuscle(HP), IFN-γ and TGF-β1 and adverse reactions were compared between the two groups. Results: After treatment, the total effective rate in the observation group was 93.33%,which was significantly higher than those in the control group 78.33%, the difference has statistically significant(P<0.05);the NIH-CPSI scores of pain and discomfort, urination symptoms, symptom severity and total scores in the observation group were significantly lower than those in the control group[(5.05±0.69) vs(6.33±0.74)scores,(1.56±0.43) vs(2.70±0.55)scores,(6.31±1.50) vs(7.92±1.64)scores,(12.92±2.44) vs(16.95±2.87)scores], the difference has statistically significant(P<0.05);the prostatic fluid WBC, IFN-γ and TGF-β1 in in the observation group were significantly lower than those in the control group[(8.52±1.70) vs(10.04±1.58)number/HP,(8.06±1.32) vs(9.72±1.61)ng/L,(27.34±3.06) vs(42.57±3.89)ng/L], the HP were significantly lower than those in the control group [(81.06±5.75) vs(70.22±6.31)%], the difference has statistically significant(P<0.05);there was no significant difference in the total incidence of nausea and vomiting, fatigue and palpitation between the two groups(P >0.05). Conclusion: On the basis of conventional treatment, the treatment of chronic ⅢA prostatitis with combination of propranolol has a significant effect, which can effectively promote the recovery of symptoms, reduce the expression of prostatic fluid IFN-γ and TGF-β1, and do not increase the adverse reactions, it’s worth popularizing.
作者
李崇巍
刘永胜
郝捷
范晓猛
路璐
崔铁峰
LI Chong-wei;LIU Yong-sheng;HAO Jie;FAN Xiao-meng;LU Lu;CUI Tie-feng(Department of Urology,Baoding Second Hospital,Baoding,Hebei,071051,China;Department of Anesthesiology,Affiliated Hospital of Hebei University,Baoding,Hebei,071000,China)
出处
《现代生物医学进展》
CAS
2020年第12期2385-2389,共5页
Progress in Modern Biomedicine
基金
河北省科技厅攻关项目(No.05276143)。
